<DOC>
	<DOCNO>NCT01090648</DOCNO>
	<brief_summary>This trial design assess swallowability uncoated film-coated 200 mg etravirine tablet HIV-1 infect patient . In addition , comparison single 200 mg tablet versus two 100 mg formulation make . The outcome trial aid making decision future commercial 200 mg formulation .</brief_summary>
	<brief_title>TMC125HIV1083 - Swallowability Uncoated 200 mg Etravirine Tablets HIV-1 Infected Patients</brief_title>
	<detailed_description>This trial design elicit swallowability two formulation 200 mg tablet etravirine ( ETR ) . The trial allow assessment swallowability 200 mg uncoated tablet , 200 mg film-coated tablet make comparison tablet current commercially available 100 mg ( uncoated ) tablet . The trial perform HIV-1 infected patient currently take etravirine ( ETR ) total daily dose 400 mg ( four 100 mg tablet , whole tablet orally ) part antiretroviral regimen virologic suppression ( &lt; 50 copies/mL least three month ) . The trial include patient already take etravirine since patient pill take experience also experience commercially available 100 mg tablet formulation . A minimum 45 patient include trial assure sample representative HIV-1 infected population . Patients give single dose etravirine ( ETR ) uncoated 200 mg tablet morning , complete questionnaire relate intake . Within 30 minute , administer coat 200 mg formulation , follow questionnaire . Assessments 200 mg tablet make single-blinded fashion . As patient administer two 200mg tablet morning , he/she need take even dose day assessment . The questionnaire use assess swallowability 200 mg formulation current 100 mg tablet , also evaluate patient preference . Patients follow safety tolerability one week due short duration patient study treatment ; difficult distinguish Adverse Events ( AEs ) result current etravirine ( ETR ) intake ( four 100 mg tablet ) versus study intake ( two 200 mg tablet ) . A single dose etravirine uncoated 200 mg tablet morning , follow completion questionnaire related intake . Within 30 minute , patient administer coated 200 mg formulation , follow questionnaire . Maximum 2 week screen , 1 day treatment , 1 week follow . Total duration participation 2 week maximum .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Etravirine</mesh_term>
	<criteria>Women must postmenopausal least 2 year , OR surgically sterile ( total hysterectomy bilateral oophorectomy , tubal ligation/bilateral tubal clip without reversal operation , otherwise incapable become pregnant ) , OR heterosexually active duration study vasectomize partner ( confirm sterile ) OR childbearing potential heterosexually active , practice highly effective method birth control ( specify ) entry , agree continue use highly effective method contraception throughout study . Women tubal ligation require use one contraceptive method ( Note : A male female condom use together due risk breakage damage cause latex friction ) All woman must negative serum urine pregnancy test screening . Women childbearing potential must negative urine pregnancy test visit Men must agree use highly effective method birth control ( i.e. , male condom either female intrauterine device , diaphragm , cervical cap nonestrogen hormonal base contraceptive ) donate sperm study Patients must sign informed consent document indicate understand purpose procedure require study willing participate study Patient comply protocol requirement Any condition , opinion investigator , would compromise study wellbeing patient prevent patient meeting perform study requirement Any active clinically significant disease ( e.g. , pancreatitis , cardiac dysfunction ) finding screen medical history , laboratory physical examination , investigator 's opinion , would compromise patient 's safety , ability swallow , outcome trial Pregnant breastfeed female patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>TMC125HIV1083</keyword>
	<keyword>TMC125</keyword>
	<keyword>HIV</keyword>
	<keyword>Etravirine</keyword>
	<keyword>ETR</keyword>
	<keyword>Intelence</keyword>
	<keyword>HIV Infections</keyword>
</DOC>